Eleazar Sukenik

Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome

Retrieved on: 
Thursday, September 22, 2022
Central nervous system, Therapy, PEA, Patent application, Food addiction, OTC Markets Group, FSE, Research, MEAI, Eleazar Sukenik, Company, Drug development, Obesity, Application, Acquisition, Hebrew language, Microdeletion syndrome, IP, Patient, CSE, Lists of diseases, Addictive Behaviors, Hebrew University of Jerusalem, Patent, NASDAQ, Associate, GLOBE, Pharmaceutical industry, Pharmacology

VANCOUVER, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced it has filed a provisional patent application related to metabolic syndromes including obesity.

Key Points: 
  • "In pre-clinical studies MEAI has shown great potential in its ability to treat different addictions.
  • Certain metabolic syndromes Can be associated to addictive behaviors, and we believe combining MEAI with SciSparc's CannAmide may create a valuable tool for treating these conditions."
  • Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder.
  • Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields 3rd Patent Application for the Treating of Obesity and Metabolic Syndromes

Retrieved on: 
Thursday, September 22, 2022
THC, Central nervous system, PEA, TEL, FSE, MEAI, Tourette syndrome, U.S. Securities and Exchange Commission, CBD, Intention, Company, Obesity, Private Securities Litigation Reform Act, Microdeletion syndrome, Status epilepticus, OTC, Lists of diseases, CSE, Technology, Pain, Hebrew University of Jerusalem, Annual report, Nasdaq, Autism, Addictive behavior, Eleazar Sukenik, Research, GLOBE, Agitation, SEC, Patent, Alzheimer's disease, Pharmaceutical industry

"Our collaboration with Clearmind focuses on treating different addictions and binge behaviors, using the benefits of our technology and Clearmind's.

Key Points: 
  • "Our collaboration with Clearmind focuses on treating different addictions and binge behaviors, using the benefits of our technology and Clearmind's.
  • "We believe that combining MEAI with SciSparc's CannAmide may create a great opportunity in treating these conditions."
  • SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists.
  • For example, SciSparc is using forward-looking statements when it discusses the ability of the combination of MEAI with SciSparc's CannAmide to successfully treat obesity and metabolic conditions.

Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer

Retrieved on: 
Monday, September 12, 2022
CFO, Plan, Compugen, Statistics, Honours degree, Business administration, TIGIT, TASE, Eleazar Sukenik, Company, Growth, Amdocs, Industry, Immunotherapy, Patient, Anat, M&A, Cancer, TEL, Hebrew University of Jerusalem, AstraZeneca, Nasdaq, Leadership, Crown Worldwide Group, Tumor microenvironment, Research, Bispecific monoclonal antibody, Pharmaceutical industry, Management, Bayer

HOLON, Israel, Sept. 12, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Alberto Sessa has been appointed Chief Financial Officer (CFO) and member of the management team.

Key Points: 
  • HOLON, Israel, Sept. 12, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Alberto Sessa has been appointed Chief Financial Officer (CFO) and member of the management team.
  • "I am delighted to have a financial executive of Alberto's expertise and experience join Compugen and strengthen our management team," said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen.
  • Alberto brings more than 30 years of industry experience to Compugen by serving in public and private companies.
  • Previously, Alberto spent seven years as Worldwide Group CFO at Nasdaq listed Amdocs with responsibility for the global financial business activities.

Airovation Technologies and ASUS Sign MOU to Expand Air Purification Solutions in Taiwan and Greater China

Retrieved on: 
Tuesday, September 6, 2022
COO, Partnership, Hebrew University of Jerusalem, Culture, ASUS, Volatile organic compound, Eleazar Sukenik, Technology, Food, Asus, CEO, Taipei Economic and Cultural Office in Australia, Research, Glass, Carbon, Solution, NESS, Virus, Sale, MOU, Superoxide, IAQ, Atmosphere, Investment, Movement, CO2, Mineral, Founder CEO, Parallel Computers, Inc., Industry, Environment, Bacteria, Electronics, Nature, Pharmaceutical industry

NESS ZIONA, Israel, Sept. 6, 2022 /PRNewswire/ -- Airovation Technologies, a cutting-edge climate tech company based in Israel, and ASUSTek Computer Inc., the Taiwan-based world leader in computer hardware and consumer electronics' applications and markets, this week signed a Memorandum of Understanding for the megacorporation to explore utilizing Airovation's air purification technology in the development, manufacturing and sale of products and solutions in Taiwan and Greater China.

Key Points: 
  • Taiwanese conglomerate looks to utilize the technology behind Airovation's patented air purification solutions to reform the development of its hardware and consumer electronics.
  • Airovation's air purification technologyprevents the negative impacts of CO2on the environment, while simultaneously improving people's productivity and wellbeing.
  • In the newly signed MOU, the two companies agree to cooperate on further developing Air-O and Airosphera, as well as ASUS' planned products and solutions.
  • Airovation completed a $16 million funding round to transform the air purification industry utilizing its groundbreaking technology, bringing its total raised funds to $19 million.

Forsea Foods to focus on relieving bottleneck in seafood supply, starting with eel meat

Retrieved on: 
Tuesday, September 6, 2022
Hebrew University of Jerusalem, Eleazar Sukenik, Food, CEO, Strauss Group, Research, Doctor of Philosophy, Nachman, Electron, Bermuda Triangle, Eel, Tel Aviv University, Cell, Developmental biology, Medicine, Bioreactor, IIA, Organoid, Sargasso Sea, Kitchen, Meat, Seafood, Microplastics, Ecosystem, Taste, Bermuda, Environment, Mercury, Aquaculture, ForSea Ferries

ASHDOD, Israel, Sept. 6, 2022 /PRNewswire/ -- With the dawn of the cell-cultured seafood making waves, a new player has landed. FoodTech start-up Forsea Foods, Ltd. announces it has brought this novel concept closer to natural perfection through its patented organoid technology.

Key Points: 
  • FoodTech start-up Forsea Foods , Ltd. announces it has brought this novel concept closer to natural perfection through its patented organoid technology.
  • The start-up announces that it is kicking off its activities by targeting the supply gaps in the eel meat market.
  • Forsea claims that they will also yield the same nutritional profile as traditionally raised seafood.
  • While Forsea can cultivate practically any type of seafood, the company says it is currently focusing its efforts on cultivating the meat of freshwater eels.

Forsea Foods to focus on relieving bottleneck in seafood supply, starting with eel meat

Retrieved on: 
Tuesday, September 6, 2022
Hebrew University of Jerusalem, Eleazar Sukenik, Food, CEO, Strauss Group, Research, Doctor of Philosophy, Nachman, Electron, Bermuda Triangle, Eel, Tel Aviv University, Cell, Developmental biology, Medicine, Bioreactor, IIA, Organoid, Sargasso Sea, Kitchen, Meat, Seafood, Microplastics, Ecosystem, Taste, Bermuda, Environment, Mercury, Aquaculture, ForSea Ferries

ASHDOD, Israel, Sept. 6, 2022 /PRNewswire/ -- With the dawn of the cell-cultured seafood making waves, a new player has landed. FoodTech start-up Forsea Foods, Ltd. announces it has brought this novel concept closer to natural perfection through its patented organoid technology.

Key Points: 
  • FoodTech start-up Forsea Foods , Ltd. announces it has brought this novel concept closer to natural perfection through its patented organoid technology.
  • The start-up announces that it is kicking off its activities by targeting the supply gaps in the eel meat market.
  • Forsea claims that they will also yield the same nutritional profile as traditionally raised seafood.
  • While Forsea can cultivate practically any type of seafood, the company says it is currently focusing its efforts on cultivating the meat of freshwater eels.

xCAT IQ Installed at Hadassah University Hospital

Retrieved on: 
Thursday, September 1, 2022
Hebrew University of Jerusalem, University, IQ, Fracture, 3D, Bed, DDS, Oral, ANN, Rothschild, Eleazar Sukenik, World Zionist Organization, Oral and maxillofacial surgery, Bone fracture, CT, Hebrew language, Department, Human, Hospital, Multimedia, Cone beam computed tomography, MD, Cholesteatoma, Surgeon, High-dependency unit, Paola Lattus, School, Hadassah Medical Center, XCAT, Prophet, Street of the Prophets, MS, Otorhinolaryngology, Dentistry, Patient, Medical imaging, Health, DMD, Hadassah Women's Zionist Organization of America

Xoran's xCAT IQ is a truly mobile cone beam CT system for soft tissue and bone imaging.

Key Points: 
  • Xoran's xCAT IQ is a truly mobile cone beam CT system for soft tissue and bone imaging.
  • With high resolution down to 70 microns and an extremely small footprint, the xCAT IQ is uniquely suited to meet the needs of the Hadassah clinicians.
  • The implementation of xCAT IQ was largely facilitated by the efforts of Prof. Yoram Weiss, MD, Director General of the Hadassah Medical Organization.
  • Since the establishment of Hadassah's first hospital on Jerusalem's Neviim Street (Street of the Prophets) - a gift of the Rothschild family in 1918 - the Hadassah University Medical Center has expanded to include two University hospitals in Jerusalem - located on Mt.

Federal Court Shoots Down Outrageous Einstein Claims On Famous Picture--by Intelink Law Group P.C.

Retrieved on: 
Monday, August 29, 2022
Hebrew University of Jerusalem, University, Eleazar Sukenik, District court, HUJ, Intelink, Death, Weapon, Hope, Hearing, Human, Albert Einstein, PALO, History, Douglas v. U.S. District Court ex rel Talk America, Johnson, Amazon, United States district court, Online gambling, Pharmaceutical industry, Counsel

PALO ALTO, Calif., Aug. 29, 2022 /PRNewswire-PRWeb/ -- In a ruling issued by Judge Manish S. Shah of U.S. District Court for the Northern District of Illinois on August 1, 2022 (1:21-cv-05492), online stores are allowed to call Albert Einstein's portrait "Albert Einstein's image" instead of "'photo of famous German scientist,' 'picture of theory of relativity scientist,' 'mousepad featuring E = mc2 physicist," as previously suggested by The Hebrew University of Jerusalem.

Key Points: 
  • His popularity has scarcely waned in the 67 years since his death, and his image appears everywhere from memes to mugs.
  • The problem: In many (perhaps all) of those claims, HUJ didn't actually own the copyrights to the images in question.
  • Different from most of those Chinese sellers, dealzEpic decided to fight back and engaged Intelink Law Group P.C.
  • Attorney Wesley Johnson, in conjunction with and Of Counsel to Intelink Law Group P.C., represents the small company.

Clearmind Medicine Announces Additional Positive Pre-Clinical Results for its Cocaine Addiction Treatment

Retrieved on: 
Wednesday, August 24, 2022
Hebrew University of Jerusalem, Eleazar Sukenik, CSE, Research, MEAI, FSE, RATS, Addiction, Animal, Bar-Ilan University, GLOBE, Crave, Therapy, Gonda, OTC Markets Group, Acquisition, Cocaine, Pharmaceutical industry, Drug

VANCOUVER, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced additional positive pre-clinical results for treatment for cocaine addiction using MEAI, its novel psychedelic molecule.

Key Points: 
  • VANCOUVER, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (Clearmind or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced additional positive pre-clinical results for treatment for cocaine addiction using MEAI, its novel psychedelic molecule.
  • "We are very excited by these new results which further strengthen our previous results indicating the potential of our proprietary MEAI to treat cocaine addiction, said Dr. Adi Zuloff-Shani, Clearmind's Chief Executive Officer.
  • As cocaine is extremely addictive and there is currently no dedicated treatment, I believe Clearmind is leading the way in this field.
  • This research demonstrates again MEAIs unique ability to treat cocaine addiction and its potential to become the first dedicated cocaine addiction treatment.

SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.

Retrieved on: 
Wednesday, August 24, 2022
CBD, Hebrew University of Jerusalem, THC, Eleazar Sukenik, CSE, Pain, OTC, Research, Central nervous system, MEAI, Risk, Status epilepticus, FSE, Tourette syndrome, SEC, Agitation, U.S. Securities and Exchange Commission, Addiction, Alzheimer's disease, Bar-Ilan University, Animal, GLOBE, Intention, Crave, TEL, Nasdaq, Company, Therapy, Cocaine, Gonda, Clinical trial, Annual report, Private Securities Litigation Reform Act, Acquisition, Autism, Rat, Pharmaceutical industry

TEL AVIV, Israel, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced additional positive pre-clinical results of its Psychedelic-based Pharma Collaboration for treatment for cocaine addiction using MEAI, a novel psychedelic molecule of Clearmind Medicine Inc. (“Clearmind”) (CSE: CMND), (OTC: CMNDF), (FSE: CWY0).

Key Points: 
  • "We are excited about these recent results in light of the potential synergistic effect between SciSparcs CannAmide and Clearminds MEAI, as previously demonstrated.
  • These results continue to indicate that we may have a targeted treatment for cocaine addiction within our reach, commented Oz Adler, SciSparc's Chief Executive Officer.
  • "These results reinforce our decision to enter a collaboration between the two companies."
  • Clearmind has established a research collaboration with the Hebrew University of Jerusalem and Bar Ilan University.